Mylan Appoints Anthony Mauro Chief Commercial Officer

HERTFORDSHIRE, England and PITTSBURGH, Feb. 22, 2016 /PRNewswire/ -- Mylan N.V. (NASDAQ, TASE: MYL) today announced the appointment of Anthony (Tony) Mauro to chief commercial officer.

In his new role, which reports to Mylan President Rajiv Malik, Mauro will now be responsible for overseeing global sales excellence and operations of all commercial markets around the world. Until his successor is appointed, Mauro will continue his current role as president of North America.

Mauro has been with Mylan for more than 20 years and has successfully led its largest commercial business – the North American region – for the last four of them. He has served the company in several capacities of increasing responsibility, including president of Mylan Pharmaceuticals Inc., the company's flagship generics division in the U.S.; chief operating officer of Mylan Pharmaceuticals ULC in Canada; vice president of North America Strategic Development; and vice president of North America Sales. Mauro also served as chairman of the board of directors for the U.S. Generic Pharmaceutical Association (GPhA) for two consecutive terms in 2012 and 2013, and prior to that served two consecutive terms as vice chairman of the board for GPhA.

Mylan CEO Heather Bresch commented: "Tony has been instrumental in Mylan's success to date, particularly in his strong leadership of our North American commercial business. During his tenure, Tony has demonstrated his ability to relentlessly drive innovation, provide our customers with exceptional and reliable service, and has maximized opportunities while overcoming challenges and consistently delivered strong financial performance. In Tony's new leadership role, Mylan will be better positioned for Tony to continue to drive sales excellence throughout all of Mylan's global commercial markets."

Mylan President Rajiv Malik added: "Tony has demonstrated a proven track record of driving success in our North Americacommercial operations and enhancing our relationships with customers, particularly as they continue to expand globally. As a result, Tony has certainly earned the opportunity to continue his success with Mylan and now by driving global sales excellence throughout our global commercial operations. I look forward to his continued strong partnership and strategic input as we continue to grow and strengthen our business in existing markets and expand our commercial footprint in new regions."

Mauro said: "I have had the privilege of being part of Mylan for more than 20 years and contributing to the company's evolution from a leading generics pharmaceutical company in the U.S. to a leading global pharmaceutical company. Mylan's future has never been brighter, and I am proud to have been recognized and ready to step up to be a part of Mylan's senior organizational leadership team as we continue our exciting growth trajectory, while delivering on our mission to set new standards in healthcare."

This press release includes statements that constitute "forward-looking statements," including with regard to Mylan being better positioned under Mauro's leadership to identify commercial opportunities and best practices across the various regions to bring even greater value to its customers around the world and to continue its efforts to provide 7 billion people access to high quality medicine; that Mylan's future has never been brighter; and about Mylan's exciting growth trajectory and its mission to set new standards in healthcare. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to: the effect of any changes in our customer and supplier relationships and customer purchasing patterns; other changes in third-party relationships; the impact of competition; changes in the economic and financial conditions of the businesses of Mylan; the scope, timing, and outcome of any ongoing legal proceedings and the impact of any such proceedings on our business; any regulatory, legal, or other impediments to our ability to bring our products to market; actions and decisions of healthcare and pharmaceutical regulators, and changes in healthcare and pharmaceutical laws and regulations, in the United States and abroad; our ability to protect our intellectual property and preserve intellectual property rights; other uncertainties and matters beyond the control of management; and the other risks detailed in the company's filings with the Securities and Exchange Commission. The company undertakes no obligation to update these statements for revisions or changes after the date of this release.

Mylan is a global pharmaceutical company committed to setting new standards in healthcare. Working together around the world to provide 7 billion people access to high quality medicine, we innovate to satisfy unmet needs; make reliability and service excellence a habit; do what's right, not what's easy; and impact the future through passionate global leadership. We offer a growing portfolio of more than 1,400 generic and branded pharmaceuticals, including antiretroviral therapies on which nearly 50% of people being treated for HIV/AIDS in the developing world depend. We market our products in approximately 165 countries and territories. Our global R&D and manufacturing platform includes more than 50 facilities, and we are one of the world's largest producers of active pharmaceutical ingredients. Every member of our nearly 35,000-strong workforce is dedicated to creating better health for a better world, one person at a time. Learn more at